Ask AI
ProCE Banner Series

Targeting BCMA in Early Relapsed/Refractory Myeloma: Translating New Clinical Evidence Into Managed Care Strategies

Join us either in-person or on-line for this live symposium at AMCP 2026 to gain detailed guidance from field experts and explore the most updated data for treating relapsed/refractory multiple myeloma using BCMA-targeted agents.

 

  ACPE
Who Should Attend

This activity is intended for oncology and managed care pharmacists and other healthcare professionals caring for patients with multiple myeloma.

All Events

Targeting BCMA in Early Relapsed/Refractory Myeloma: Translating New Clinical Evidence Into Managed Care Strategies

Upcoming Events

April

14

2026

11:30 AM - 1:30 PM Central Time (CT)

In-person

TBD

12:00 PM - 1:30 PM Central Time (CT)

Virtual

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact Customer Support prior to the live event.

CME/CE Info

Goal Statement
This activity aims to improve learners’ knowledge, competence, and confidence in evaluating and applying emerging BCMA-targeted agents in treatment plans for patients with relapsed/refractory multiple myeloma, ultimately improving patient outcomes.

Target Audience
This activity is intended for oncology and managed care pharmacists and other healthcare professionals caring for patients with multiple myeloma.

Learning Objectives
Upon completion of this activity, participants should be able to:

  • Assess the rationale for targeting BCMA in early R/R MM and analyze implications for formulary inclusion and treatment approaches to improve patient outcomes

  • Summarize recent updates on BCMA-targeted therapies for R/R MM, integrating these insights into internal clinical guidelines, formulary reviews, and patient/physician education

  • Develop and implement evidence-based strategies for monitoring and managing ocular toxicity with BCMA-targeted antibody–drug conjugates by establishing protocols, supporting coverage decisions, and facilitating multidisciplinary communication

  • Synthesize managed care perspectives when implementing BCMA-directed therapy in clinical practice

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Continuing Pharmacy Education

Clinical Care Options, LLC dba Decera Clinical Education designates this continuing education activity for 1.5 contact hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-26-075-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest
Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

Clinical Care Options, LLC dba Decera Clinical Education

Supporters

This educational activity is supported by independent medical education grants from GSK and Johnson & Johnson.

GSK

Johnson & Johnson

For customer support please click here.

Mailing Address:

 

Decera Clinical Education
12001 Sunrise Valley Drive
Suite 304
Reston, VA 20191